Research institutionUnited Statesmskcc.org
Memorial Sloan Kettering Cancer Center is a leading non-profit cancer treatment and research institution located in New York City, United States. It provides high-quality patient care for individuals diagnosed with various forms of cancer, utilizing advanced diagnostic tools, surgical procedures, radiation therapy, and chemotherapy regimens tailored to individual needs.
The organization is heavily involved in biomedical research, with a particular emphasis on understanding cancer biology, developing new therapeutic strategies, and conducting clinical trials to evaluate innovative treatments. Its research programs cover a wide range of topics including genetics, immunology, and epidemiology of cancer.
Memorial Sloan Kettering operates several campuses and outpatient facilities in the New York area and maintains affiliations with medical schools such as Weill Cornell Medical College. It also offers educational programs for medical students, residents, and fellows, contributing to the training of future oncology professionals.
As a prominent player in the healthcare and research sectors, the center collaborates with pharmaceutical companies, government agencies, and international organizations to advance cancer research and improve patient outcomes. Its contributions have led to numerous breakthroughs that have shaped modern oncology practices worldwide.
Also known as Memorial Sloan-Kettering Cancer Center.
None yet. When a new project in the record names MSKCC as owner, partner or investor, it shows here.
Oral helicase‑primase inhibitor pritelivir is the first novel‑mechanism FDA‑approved HSV therapy in ~30 years; Phase 3 showed 63% vs 34% healing by Day 28. US availability expected before end of 2026.
Phase 3 trial of subcutaneous T‑cell‑engaging bispecific with R‑CHOP cut progression/death risk by 51% in newly diagnosed DLBCL (IPI 2–5); safety consistent with known profiles.
FDA grants full approval to the all‑oral imlunestrant + abemaciclib combination for adults with ER+, HER2–, ESR1‑mutated advanced or metastatic breast cancer after prior endocrine therapy.
FDA clears zidesamtinib for adults with advanced ROS1‑positive NSCLC after prior ROS1 inhibitor; ARROS‑1 showed 44% ORR and durable responses, including in brain metastases.
Interim phase II results met primary endpoint (cCR12); trial suggests some patients may avoid chemo, radiation and surgery. Data to be shared with regulators including for US accelerated review.
